Dr. Cortes Discusses FLT3 Inhibitors in AML

J‚Äčorge E. Cortes, MD
Published: Thursday, Jun 22, 2017



Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 


Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x